Lars Fruergaard Jørgensen, Novo Nordisk CEO (Graeme Sloan/Sipa USA)(Sipa via AP Images)
May 7, 2025 06:52 AM EDTUpdated 10:41 AM
Pharma

No­vo Nordisk trims growth fore­cast as GLP-1 com­pounder ban yet to go live

Elizabeth Cairns

Senior biopharma journalist

No­vo Nordisk said on Wednes­day that com­pound­ing phar­ma­cies’ pro­duc­tion of its GLP-1 med­i­cine semaglu­tide had re­duced its mar­ket pen­e­tra­tion more dra­mat­i­cal­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

PhRMA says tar­iffs are 'not the an­swer' as in­dus­try trade probe clos­es for com­ments

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times